KYUSHU UNIVERSITY

CLEAR biomarker analyses show Lenvatinib + Pembrolizumab (L+P) significantly improved efficacy over Sunitinib in advanced RCC. No associations found between PD-L1 levels, gene-signature scores, or molecular subtypes with PFS for L+P. Sunitinib showed shorter PFS with high proliferation and MYC signature scores, longer with high angiogenesis scores. Six new molecular subtypes defined, with no association to PFS for either treatment.